Phaseline

Targets › IL22

IL22 (Interleukin-22): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Cytokine that plays a critical role in modulating tissue responses during inflammation. Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage. (UniProt, Q9GZX6)

Open in Phaseline: the race on IL22, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalCP-IL22BP mRNA
IL-22 binding protein (IL-22BP) delivered via cationic peptide; IL-22 axis inhibitor
IL22Phase 1mRNA VaccineJun 2027
Xingchen PengIL-22BP/LNP compound
IL-22BP mRNA vaccine
IL22Phase 1Refractory Malignant Solid Tumors–

Conditions

mRNA Vaccine (1) Refractory Malignant Solid Tumors (1)

Modalities

other (2)

Companies

West China Hospital (1) Xingchen Peng (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.